Las Vegas – September 21, 2026 -- Concept Medical's MagicTouch sirolimus-coated balloon will face fresh scrutiny at VIVA 2026 as researchers unveil new subgroup data from the SirPAD randomized trial covering 597 patients treated for femoropopliteal peripheral artery disease without tissue loss.

Shanghai – September 20, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Atlanta and Los Angeles – September 20, 2026 -- StimCardio Medical reported that patients treated with non-invasive median nerve stimulation (MNS) after atrial fibrillation (AF) ablation showed 90.0% freedom from atrial arrhythmias at six months, compared with 80.8% for those receiving sham treatment, though the difference did not reach statistical significance. The randomized, double-blind, sham-controlled NeuroPulse pilot study was presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the peer-reviewed journal Heart Rhythm.

Seoul – September 16, 2026 -- A phase III trial of tambotatug pelitecan (Tam-Peli, YL201), an anti-B7-H3 antibody-drug conjugate, cut the risk of death by 54% compared with standard-of-care topotecan in patients with relapsed small-cell lung cancer (SCLC), according to data presented at the IASLC 2026 World Conference on Lung Cancer.

Seoul – September 16, 2026 -- Risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, reduced the risk of death by 54% compared with topotecan in patients with relapsed small-cell lung cancer, according to Phase III ARTEMIS-008 trial results presented at the IASLC 2026 World Conference on Lung Cancer.

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.